New drug "Lai Ruichi Bevacizumab" developed by Eli Lilly (LLY.US) has applied for listing in China, with global sales expected to reach $400 million by 2025.

On March 3, according to the official website of the China National Medical Products Administration Drug Evaluation Center (CDE), the market application for the new drug Lebrikizumab Injection, a type 3.1 drug submitted by Eli Lilly (LLY.US), has been accepted for review. Public information indicates that Lebrikizumab is a monoclonal antibody that inhibits interleukin-13 (IL-13) and selectively blocks IL-13 signaling with high affinity. This drug is the first IL-13 antibody submitted for market approval in China. Based on public information and clinical trial progress, the indication for this application is speculated to be atopic dermatitis. Lebrikizumab is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and slow dissociation rates. The binding site of Lebrikizumab with the IL-13 cytokine overlaps with the binding site of IL-4R subunit in the IL-13 receptor alpha 1/IL-4R heterodimer, thereby preventing the formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is a major cytokine of atopic dermatitis, driving type 2 inflammation in the skin leading to skin barrier dysfunction, itchiness, skin thickening, and infections. Lebrikizumab has been approved for marketing in the EU, Japan, and the US between 2023 and 2024 for the treatment of adolescents aged 12 and older and adults with moderate to severe atopic dermatitis (AD). Eli Lilly holds exclusive rights to develop and commercialize Lebrikizumab in the US and global regions outside of Europe. According to Eli Lilly's 2025 report, global sales of Lebrikizumab are approximately $408 million. It is understood that there are currently only two IL-13 antibodies approved for marketing globally, including Leo Pharma's Tralokinumab and Eli Lilly's Lebrikizumab.